Connect with us

Healthcare

REPORT: New oral medicine reduces COVID-19 hospitalizations and deaths

Published

on

coronavirus covid 19

Medical research company Merck announced Friday that their investigational oral antiviral medicine reduced the number of hospitalized COVID-19 patients. In addition, it reduced deaths as well. Ridgeback Biotherapeutics teamed up on the study Now, the companies are seeking emergency use authorization in the United States.

Nearly 1,550 COVID positive patients were a part of the study. Every single one had at least one risk factor. Out of those, only 7.3% of those who received the medicine, molnupiravir, hospitalized themselves as a result of their illness. Meanwhile, out of the control group of the study, 14.1% either died or visited a hospital. After 29 days, eight people who did not receive the medicine died while not a single person who received it died.

Merk’s CEO and President Robert M. Davis hopes that this will ease the strain caused by the virus. “With these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic and will add to Merck’s unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most,” Davis said.

Ridgeback Biotherapeutics CEO Wendy Holman was equally optimistic. “We are very encouraged by the results from the interim analysis and hope molnupiravir, if authorized for use, can make a profound impact in controlling the pandemic,” Holman said.

Should President Biden authorize molnupiravir it would be the first oral medicine to treat COVID-19.

You can follow Jenny Goldsberry on Twitter @jennyjournalism.

You may like

Continue Reading

Nation

Elizabeth Warren Acknowledges Unintended Consequences of Obamacare

Published

on

Elizabeth Warren

Senator Elizabeth Warren of Massachusetts, a longtime supporter of the Affordable Care Act, commonly known as Obamacare, is now acknowledging the unintended consequences of the healthcare legislation, particularly its impact on industry consolidation and rising healthcare prices.

Warren, who has been a vocal proponent of Obamacare, has recently had what the Wall Street Journal reported as an “epiphany” regarding the consequences of the healthcare law. In a letter addressed to the Health and Human Services Department inspector general, Warren, along with Senator Mike Braun of Indiana, expressed concerns about vertically-integrated healthcare companies potentially increasing prescription drug costs and evading federal regulations.

According to reports from Fox News, the bipartisan letter highlighted issues with the nation’s largest health insurers allegedly bypassing Obamacare’s medical loss ratio (MLR). According to Warren, these insurers, through vertical integration, have manipulated the system, leading to “sky-high prescription drug costs and excessive corporate profits.”

The senators detailed how conglomerates, like UnitedHealth Group, with ownership across various healthcare sectors, could inflate medical payments to pharmacies and, by realizing those payments on the pharmacy side, appear to comply with MLR requirements while retaining more profits.

Moreover, despite the Democrats’ argument that the MLR would benefit patients, it has incentivized insurers to merge with or acquire pharmacy benefit managers (PBMs), retail and specialty pharmacies, and healthcare providers. This, in turn, has made healthcare spending less transparent, as insurers can allegedly shift profits to their affiliates by increasing reimbursements.

Warren, who has consistently voted against Obamacare repeal efforts, notably advocated for a “Medicare for All” proposal during her 2020 presidential campaign. Despite her prior support for the healthcare law, Warren’s recent concerns about its unintended consequences have raised questions about the long-term effects of Obamacare and its impact on the healthcare industry.

You may like

Continue Reading

Trending